Rezolute Inc. Common Stock (NV) (RZLT)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor in the Buffett-Graham tradition, I start with business quality and price. Rezolute is a clinical-stage rare disease company with 58 employees. Its lead asset, ersodetug, is in Phase 3 for tumor hyperinsulinism and congenital hyperinsulinism. That is a focused, potentially high-value niche, but there is no product revenue, so no economic moat can yet be demonstrated. The filed figures show net losses of $68.5 million in fiscal year 2024, the year ended 2024-06-30; $74.4 million in fiscal year 2025, the year ended 2025-06-30; and $77.6 million in fiscal year 2026, the year ended 2026-06-30. In fiscal Q3 2026, the quarter ended 2026-03-31, the net loss was $16.2 million, or $0.16 per diluted share, versus a $18.9 million loss in fiscal Q3 2025, the quarter ended 2025-03-31. The annual loss trend is not encouraging, and trailing free cash flow is negative $73.5 million, a negative 16.5% FCF yield on the $445.9 million market cap at the 2026-10-13 close. Financial health is mixed: debt is tiny with a D/E of 0.01, and the Altman Z-score is 26.97, but Piotroski is 2/9, ROE is -59.04%, and ROCE is -35.32%. Valuation gives no margin of safety on current numbers: FairStock calculations show P/B of 4.43, P/E of -5.76, and a FairStock Score of 26/100. The 52-week range of $1.07 to $11.46 shows how violently the market prices clinical hope and fear. Growth trajectory depends entirely on trial outcomes, not on present earnings. I would need evidence of durable cash generation and a much lower price before calling this a Graham-style bargain.

In plain English: Rezolute is a small biotech company trying to make a treatment for dangerously low blood sugar in people with rare diseases. It has no revenue and has lost money for years, so the business looks weak on today’s numbers. At $4.61 a share, the price looks expensive compared with those results because buyers are paying for hoped-for future drug success rather than current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer